Combining TNFR2-Expressing Tregs and IL-6 as Superior Diagnostic Biomarkers for High-Grade Serous Ovarian Cancer Masses

Combining TNFR2-Expressing Tregs and IL-6 as Superior Diagnostic Biomarkers for High-Grade Serous Ovarian Cancer Masses

We hypothesised that the inclusion of immunosuppressive and inflammatory biomarkers in HGSOC patients would improve the sensitivity and specificity of the preoperative marker prediction of malignancy in patients with ovarian masses. We tested a panel of 29 soluble immune factors by multiplex bead im...

Full description

Bibliographic Details
Main Authors:	Nirmala Chandralega Kampan, Apriliana Ellya Ratna Kartikasari, Cyril Deceneux, Mutsa Tatenda Madondo, Orla M. McNally, Katie Louise Flanagan, Norhaslinda A. Aziz, Andrew N. Stephens, John Reynolds, Michael A. Quinn, Magdalena Plebanski
Format:	Article
Language:	English
Published:	MDPI AG 2023-01-01
Series:	Cancers
Subjects:	progression-free survival interleukin 6 high-grade serous ovarian cancer epithelial ovarian cancer tumour necrosis factor 2 receptor regulatory T cells
Online Access:	https://www.mdpi.com/2072-6694/15/3/667

Similar Items

Mapping Epitopes Recognised by Autoantibodies Shows Potential for the Diagnosis of High-Grade Serous Ovarian Cancer and Monitoring Response to Therapy for This Malignancy
by: Rhiane Moody, et al.
Published: (2021-08-01)

A case of synchronous serous ovarian cancer and uterine serous endometrial intraepithelial carcinoma
by: Maho Shimizu, et al.
Published: (2021-06-01)

Digital pathology-based study of cell- and tissue-level morphologic features in serous borderline ovarian tumor and high-grade serous ovarian cancer
by: Jun Jiang, et al.
Published: (2021-01-01)

Cell Origins of High-Grade Serous Ovarian Cancer
by: Jaeyeon Kim, et al.
Published: (2018-11-01)

Frequency of serous tubal intraepithelial carcinoma (STIC) in patients with high grade serous ovarian cancer
by: Jung Mi Byun, et al.
Published: (2023-01-01)

Immunoexpression of p53 and p16 in Low and High-grade Serous Ovarian Cancer: A Cross-sectional Study
by: Ranajit Mandal, et al.
Published: (2023-11-01)

Development of Low-Grade Serous Ovarian Carcinoma from Benign Ovarian Serous Cystadenoma Cells
by: Puja Dey, et al.
Published: (2022-03-01)

Management of the Elderly Patients with High-Grade Serous Ovarian Cancer in the REAL-WORLD Setting
by: Michalis Liontos, et al.
Published: (2021-03-01)

BDP1 as a biomarker in serous ovarian cancer
by: Stephanie Cabarcas‐Petroski, et al.
Published: (2023-03-01)

Proteome profiling of low grade serous ovarian cancer
by: Haniyeh Bashi zadeh fakhar, et al.
Published: (2019-07-01)

Lipid Droplet Accumulation Independently Predicts Poor Clinical Prognosis in High-Grade Serous Ovarian Carcinoma
by: Naoyuki Iwahashi, et al.
Published: (2021-10-01)

The Uncertain Benefit of Adjuvant Chemotherapy in Advanced Low-Grade Serous Ovarian Cancer and the Pivotal Role of Surgical Cytoreduction
by: Racheal Louise Johnson, et al.
Published: (2021-12-01)

Chemotherapy is not necessary for early-stage serous and endometrioid ovarian cancer after undergoing comprehensive staging surgery
by: Shuqing Li, et al.
Published: (2020-08-01)

High-grade serous ovarian carcinoma organoids as models of chromosomal instability
by: Maria Vias, et al.
Published: (2023-05-01)

Prognostic Value of TNFR2 and STAT3 among High-Grade Serous Ovarian Cancer Survivors According to Platinum Sensitivity
by: Janisha Silva Raju, et al.
Published: (2021-03-01)

Identification of an Individualized Prognostic Biomarker for Serous Ovarian Cancer: A Qualitative Model
by: Fengyuan Luo, et al.
Published: (2022-12-01)

Molecular Management of High-Grade Serous Ovarian Carcinoma
by: Paula Punzón-Jiménez, et al.
Published: (2022-11-01)

A Rare Case of Collision Tumours of the Ovary: An Ovarian Serous Cystadenoma Coexisting with Fibrothecoma
by: Michele Mongelli, et al.
Published: (2022-11-01)

CA-125 Levels Are Predictive of Survival in Low-Grade Serous Ovarian Cancer—A Multicenter Analysis
by: Christoph Wohlmuth, et al.
Published: (2022-04-01)

Hormone Receptor Expression in Primary and Recurrent High-Grade Serous Ovarian Cancer and Its Implications in Early Maintenance Treatment
by: Marcus Vetter, et al.
Published: (2022-11-01)

The fading guardian: clinical relevance of TP53 null mutation in high-grade serous ovarian cancers
by: Chiara M. Biatta, et al.
Published: (2023-08-01)

MicroRNA Expression Profiles in Human Samples and Cell Lines Revealed Nine miRNAs Associated with Cisplatin Resistance in High-Grade Serous Ovarian Cancer
by: Marienid Flores-Colón, et al.
Published: (2024-03-01)

Bevacizumab Treatment for Low-Grade Serous Ovarian Cancer: A Systematic Review
by: Caitlin Lazurko, et al.
Published: (2023-09-01)

Can Nidogen-1 and Nidogen-2 improve our preoperative cancer detection rate?
by: Agnieszka Kwiatkowska, et al.
Published: (2021-06-01)

Comparison of stage III mucinous and serous ovarian cancer: a case-control study
by: Zeliha Firat Cuylan, et al.
Published: (2018-10-01)

Up-regulation of GSTT1 in serous ovarian cancer associated with resistance to TAXOL / carboplatin
by: Jing Zhang, et al.
Published: (2021-09-01)

Reduced Gonadotrophin Receptor Expression Is Associated with a More Aggressive Ovarian Cancer Phenotype
by: Janelle Cheung, et al.
Published: (2020-12-01)

The Role of the Extracellular Matrix and Tumor-Infiltrating Immune Cells in the Prognostication of High-Grade Serous Ovarian Cancer
by: Yuri Belotti, et al.
Published: (2022-01-01)

Ovarian collision tumour consisting of a fibroma and a serous cystadenoma: A case report
by: Anwar Rjoop, et al.
Published: (2024-06-01)

Epigenetic Therapy Augments Classic Chemotherapy in Suppressing the Growth of 3D High-Grade Serous Ovarian Cancer Spheroids over an Extended Period of Time
by: Michelle Bilbao, et al.
Published: (2021-11-01)

Multitask prediction models for serous ovarian cancer by preoperative CT image assessments based on radiomics
by: Le Fu, et al.
Published: (2024-02-01)

RETRACTED ARTICLE: CYPA promotes the progression and metastasis of serous ovarian cancer (SOC) in vitro and in vivo
by: Zhi-Ying Qi, et al.
Published: (2019-11-01)

A comprehensive immunohistochemical analysis of 26 markers in 250 cases of serous ovarian tumors
by: Kristýna Němejcová, et al.
Published: (2023-02-01)

Clinical analysis and artificial intelligence survival prediction of serous ovarian cancer based on preoperative circulating leukocytes
by: Ying Feng, et al.
Published: (2022-05-01)

Potential Impact of Human Cytomegalovirus Infection on Immunity to Ovarian Tumours and Cancer Progression
by: Momodou Cox, et al.
Published: (2021-03-01)

Targeted Mutational Analysis of Circulating Tumor DNA to Decipher Temporal Heterogeneity of High-Grade Serous Ovarian Cancer
by: Lara Paracchini, et al.
Published: (2022-07-01)

Mechanisms of High-Grade Serous Carcinogenesis in the Fallopian Tube and Ovary: Current Hypotheses, Etiologic Factors, and Molecular Alterations
by: Isao Otsuka
Published: (2021-04-01)

MS: Wip1 suppresses angiogenesis through the STAT3-VEGF signalling pathway in serous ovarian cancer
by: Sheng Yin, et al.
Published: (2022-05-01)

Insights into high-grade serous carcinoma pathobiology using three-dimensional culture model systems
by: Emily Tomas, et al.
Published: (2023-04-01)

The Claudin-Low Subtype of High-Grade Serous Ovarian Carcinoma Exhibits Stem Cell Features
by: Chiara Romani, et al.
Published: (2021-02-01)